US 11,788,102 B2
CHO integration sites and uses thereof
Ying Shen, Yorktown Heights, NY (US); Darya Burakov, Tarrytown, NY (US); Gang Chen, Yorktown Heights, NY (US); and James P. Fandl, LaGrangeville, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Sep. 19, 2019, as Appl. No. 16/575,506.
Application 16/575,506 is a continuation of application No. 15/783,525, filed on Oct. 13, 2017, abandoned.
Application 15/783,525 is a continuation of application No. 14/919,300, filed on Oct. 21, 2015, granted, now 9,816,110, issued on Nov. 14, 2017.
Claims priority of provisional application 62/067,774, filed on Oct. 23, 2014.
Prior Publication US 2020/0002732 A1, Jan. 2, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/85 (2006.01); C12N 15/90 (2006.01)
CPC C12N 15/907 (2013.01) [C12N 15/85 (2013.01)] 22 Claims
 
1. An isolated Chinese hamster ovary (CHO) cell comprising an exogenous nucleic acid sequence integrated within a locus of the genome of the CHO cell, wherein the locus comprises a nucleotide sequence that is at least 98% identical to SEQ ID NO:1 or SEQ ID NO: 4.